

ASX ANNOUNCEMENT

APPOINTMENT OF COMPANY SECRETARY

SYDNEY, **Tuesday**, **16 July 2013**: **Cellmid Limited (ASX: CDY)** is pleased to announce that Ms Jillian McGregor has been appointed as joint Company Secretary effective today.

Ms McGregor will act as Company Secretary with the existing Company Secretary, Nicholas Falzon.

Ms McGregor regularly advises companies and directors on regulatory compliance and corporate legal matters having spent in excess of 15 years working as a corporate lawyer in both mid and top tier Australian commercial law firms.

She has recently been appointed as Company Secretary of OncoSil Medical Limited (ASX: OSL).

Ms McGregor holds degrees in commerce and law.

End

Contact: Maria Halasz, CEO T +612 9221 6830

Cellmid Limited (ASX: CDY)

Cellmid is an Australian biotechnology company developing innovative novel therapies and diagnostic tests for inflammatory diseases, heart attack and cancer. Cellmid holds the largest and most comprehensive portfolio of intellectual property related to midkine and midkine antagonists globally. The Company's most advanced development programme is for the treatment of inflammatory disorders and cancer using its large portfolio of anti-midkine antibodies.

Elevated midkine concentration in the blood and other body fluids is strongly indicative of cancer. Cellmid is commercialising midkine as a biomarker for cancer diagnosis. The first product with midkine as one of the markers, CxBladder, was launched in the US in early 2013.

In 2010 Cellmid set up a dedicated subsidiary, Advangen International Pty Ltd, for the development of midkine for hair growth. Through this subsidiary, the Company acquired exclusive rights in certain territories to a range of hair growth products utilising FGF-5 inhibition technology. The products have since been successfully listed with the TGA and launched on the Australian pharmacy market. The Company intends to expand the distribution of these products internationally in the future.